Tack et al. (2026)
- Authors: Matthias Tack, Rosalie Gruber, Leia Betting, Swetlana Herbrandt, Shuling Wu, Barbara Schlößer, Peter Häussermann, Marc Maegele, Gerlinde Schlang, Frauke Mattner
- Institutes: Kliniken Köln (City of Cologne Municipal Hospitals), Cologne, Germany, Witten/Herdecke University, Witten, Germany
- Publisher: Medicina (MDPI)
- Link: DOI
Summary
This research provides a crucial lower-bound estimate of ME/CFS incidence after COVID-19 in a frontline workforce. By identifying specific biological markers like EBV reactivation and autoantibodies, it helps validate the physical nature of these symptoms. The study also offers a clear diagnostic pathway for occupational health assessments in healthcare settings.
What was researched?
The study aimed to determine the incidence and clinical characteristics of Post-COVID-19 syndrome and ME/CFS within a prospective cohort of hospital employees following SARS-CoV-2 infection.
Why was it researched?
Persistent fatigue is a frequent complication of COVID-19, and researchers sought to identify the proportion of patients who meet strict diagnostic criteria for ME/CFS compared to general post-viral fatigue.
How was it researched?
Researchers followed a cohort of 221 hospital employees who tested positive for SARS-CoV-2 between 2020 and 2021. Participants with persistent fatigue underwent comprehensive evaluations, including the Canadian Consensus Criteria for ME/CFS, cognitive testing, and blood analysis for autoantibodies and viral markers.
What has been found?
The study found that 11.8% of the employees reported persistent fatigue, while 3.2% were diagnosed with ME/CFS. Laboratory results showed possible EBV reactivation in over 86% of the fatigue cases and elevated autoantibodies against G-protein-coupled receptors in 66.6% of participants.
Discussion
The study’s strength is its defined source cohort, which avoids the selection bias typical of clinic-based studies. However, the small size of the final assessment group and the reliance on a single hospital system are notable limitations.
Conclusion & Future Work
ME/CFS is a significant long-term consequence for a distinct subset of individuals after COVID-19. The findings suggest that viral reactivation and autoantibody production may play key roles in the development of the condition.